Literature DB >> 26669792

Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers.

Mark H Kuniholm1, Terry Leach2, Joseph Lunievicz3, Noemí Olivo2, Kathryn Anastos1,4, Yvette Vazquez2, Mark Brennan-Ing3,5, Stephen E Karpiak3,5, Oladipo Alao2, Denis Nash6, Jerome Ernst2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26669792      PMCID： PMC5586150          DOI： 10.1089/apc.2015.0240

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  11 in total

1.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.

Authors:  José Vicente Fernández-Montero; Pablo Barreiro; Eugenia Vispo; Pablo Labarga; Clara Sánchez-Parra; Vicente Soriano
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

Review 3.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

4.  The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.

Authors:  Jennifer R Kramer; Marc A Kowalkowski; Zhigang Duan; Elizabeth Y Chiao
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

5.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Authors:  Anu Osinusi; Kerry Townsend; Anita Kohli; Amy Nelson; Cassie Seamon; Eric G Meissner; Dimitra Bon; Rachel Silk; Chloe Gross; Angie Price; Mohammad Sajadi; Sreetha Sidharthan; Zayani Sims; Eva Herrmann; John Hogan; Gebeyehu Teferi; Rohit Talwani; Michael Proschan; Veronica Jenkins; David E Kleiner; Brad J Wood; G Mani Subramanian; Phillip S Pang; John G McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyam Kottilil
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

Review 6.  The burden of liver disease in human immunodeficiency virus-infected patients.

Authors:  Massimo Puoti; Maria Cristina Moioli; Giovanna Travi; Roberto Rossotti
Journal:  Semin Liver Dis       Date:  2012-07-03       Impact factor: 6.115

7.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

Review 8.  Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa.

Authors:  Philippa C Matthews; Anna Maria Geretti; Philip J R Goulder; Paul Klenerman
Journal:  J Clin Virol       Date:  2014-06-05       Impact factor: 3.168

9.  HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study.

Authors:  Fujie Zhang; Hao Zhu; Yasong Wu; Zhihui Dou; Yao Zhang; Nora Kleinman; Marc Bulterys; Zunyou Wu; Ye Ma; Decai Zhao; Xia Liu; Hua Fang; Jing Liu; Wei-Ping Cai; Hong Shang
Journal:  Lancet Infect Dis       Date:  2014-10-07       Impact factor: 25.071

10.  Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Authors:  Mark Sulkowski; Christophe Hezode; Jan Gerstoft; John M Vierling; Josep Mallolas; Stanislas Pol; Marcelo Kugelmas; Abel Murillo; Nina Weis; Ronald Nahass; Oren Shibolet; Lawrence Serfaty; Marc Bourliere; Edwin DeJesus; Eli Zuckerman; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal:  Lancet       Date:  2014-11-11       Impact factor: 202.731
View more
  4 in total

Review 1.  The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.

Authors:  David C Perlman; Ashly E Jordan
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

2.  Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.

Authors:  Philip R Spradling; Jian Xing; Loralee B Rupp; Anne C Moorman; Stuart C Gordon; Mei Lu; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Scott D Holmberg
Journal:  J Clin Gastroenterol       Date:  2018-08       Impact factor: 3.062

3.  HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.

Authors:  Daniel Radwan; Edward Cachay; Oluwaseun Falade-Nwulia; Richard D Moore; Ryan Westergaard; William Christopher Mathews; Judith Aberg; Laura Cheever; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

Review 4.  Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua.

Authors:  David C Perlman; Ashly E Jordan; Denis Nash
Journal:  Front Public Health       Date:  2017-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.